When was SpeciCare founded?

SpeciCare was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is SpeciCare located?

SpeciCare is headquartered in Gainesville, United States.

How many employees does SpeciCare have?

As of Jun 30, 2026, the latest employee count at SpeciCare is 11.

Is SpeciCare a funded company?

SpeciCare is a funded company, having raised a total of $2.38M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 13, 2016.

When was the latest funding round of SpeciCare?

SpeciCare's latest funding was a $***** Seed round on May 20, 2020, with participation from 0 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $1.35B in funding in 2026 to date.

Where does SpeciCare rank among its competitors?

SpeciCare ranks 182nd amongst 357 active competitors, of which 122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Adela, which secured $5M in Apr, 2026.

Who are the top competitors of SpeciCare?

SpeciCare's top competitors include MedGenome, Geneoscopy and Intellia Therapeutics. Among them, Adela secured the most recent funding round in April, 2026.

SpeciCare - 2026 Company Profile, Team, Funding & Competitors

SpeciCare is a seed company based in Gainesville (United States), founded in 2015 by Ken Dixon. It operates as a Cancer care management platform. SpeciCare has raised $2.38M in funding. The company has 357 active competitors, including 122 funded and 79 that have exited. Its top competitors include companies like MedGenome, Geneoscopy and Intellia Therapeutics.

Company Details

SpeciCare ( Formerly, Specimatch) is a cancer care management platform. Based on the user's current genetic and clinical profile, the platform searches database of over 250,000 clinical trials, cancer drugs, and other oncology products to determine best treatment option for the patients. In addition, the platform also provides tools for the users to create caner care timeline. Offers service for care providers as well.

Website: specicare.com
Social
Email ID: *****@specicare.com
Part Of

Key Metrics

Founded Year

2015

Location

Gainesville, United States

Stage

Seed

Total Funding

$2.38M in 3 rounds

Latest Funding Round

Seed, May 20, 2020, $*****

Ranked

182^nd among 357 active competitors

Employee Count

11 as on Jun 30, 2026

Similar Companies

MedGenome & 504 more

View SpeciCare's full profile

SpeciCare is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
B4CC, Inc CIN: 473709663 , United States, Active	Dec 31, 2014	-	-	-

SpeciCare has raised a total funding of $2.38M over 3 rounds. Its first funding round was on Dec 13, 2016.

Here is the list of recent funding rounds of SpeciCare:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 20, 2020	8803887	Seed	3202405	3248622	1652510	1635607
Nov 27, 2017	3338304	Seed	6068453	2170045	3985285	6710068
Dec 13, 2016	9525595	Seed	3723966	7658228	7469074	3172350

Access funding benchmarks and valuations. Sign up today!

View details of SpeciCare's funding rounds and investors

The founders of SpeciCare is Ken Dixon.

Here are the details of SpeciCare's key team members:

Ken Dixon: Founder of SpeciCare.
Contact Info: 1 email address

View details of SpeciCare's Founder profiles and Board Members

SpeciCare's employee count trend

SpeciCare has 11 employees as of Jun 26. Here is SpeciCare's employee count trend over the years:

Uncover SpeciCare's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SpeciCare include MedGenome, Geneoscopy and Intellia Therapeutics. Here is the list of Top 10 competitors of SpeciCare, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	71/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
3rd	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Orbimed & 10 others	66/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	66/100
5th	Adela 2021, San Francisco (United States), Series A	Developer of a platform for detection of cancer	$139M	F-Prime Capital, LabCorp & 5 others	62/100
6th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Foresite Capital & 11 others	62/100
7th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
8th	Exicure 2009, Skokie (United States), Public	developer of gene silencing & immunomodulatory drugs using spherical nucleic acid (SNA) technology	$72.3M	Abbott Biotech Ventures, Luye Pharma & 18 others	61/100
9th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Jennison, Perceptive Advisors & 17 others	61/100
10th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
182nd	SpeciCare 2015, Gainesville (United States), Seed	Cancer care management platform	$2.38M	-	31/100